Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit of VELETRI is substantial in PAH. |
Clinical Added Value
| no clinical added value |
In PAH : VELETRI (epoprostenol), a hybrid medicine based on FLOLAN and its generics which has a new pharmaceutical form extending the stability of the solution at room temperature, does not provide any improvement in actual benefit (level V,non-existent) in comparison with these proprietary medicinal products. |
eNq1mFFv2jAQx9/5FFHeSUhXoJ0C1cZgQ2pVRos27QWZ5ChmqZ2ebaD79HMI3ejkqMPgx8TJ/86+v38+Ob7aPGbeClBQzjp+FDR8D1jCU8oeOv7kflC/8K+6tXhJVmTvs3bQCKIz30syIkTHL0aDGRAmgu83159A/w/od2tezGdLSOSr75SkWfCFiMUNyYtvvHjFaeo9glzwtOPnSm7ferGQqLPorjn+FDlJIA53b/ZHl9Pz/fdxWIj9h6oSgNeEPRhFgVlpJgoRmOwRCQ8cnyvyfWelTcUYBFeYwIjIxQj5iqaQGkPMSSbAKsh8nd4BrjKQRRCjeLhMHoWVOFmSzRiehuakP+jRntzIeqMetdvnjfPLZrPVbkZWoXBvqcxV0JMIk2nUbkWtRjMEFq5AzxqpZW1GHCXJHFWFit5rYzmKg/D0ZvVTKvKMPAdLkdsuFUGihwH19nc3kWIG96iBlOk1+0efqSwLD8x6ssOFo4wLGvW4YrKCGoOx7UL0OJOwqa6oHejkZudFCuJ0sr84M0N+pGYZTWyRpqGjQMjJeFhNtFPC4CMRMEF3NPhGWcrX4vSU2a+qo+zzLSiNojmm0fTs8qIVNZvWm+iHtlDFCdNXyHMINX+oOAYrQzbnxwJFu9Is9eLJk9lx2+fwhGRQ0enULdmiffjSmDlzurtdVA4YRT/3723t8VUBPt9tH43SNO38KawdeF3QXJuxMvHDrV3ucCc9sEIzORZS5uJ9GK7X62BBRF0QvUrBHE9O9r3D1F0H7uTELjuYko6OUp+Vx95hFbLdaW+d6cf2qbv/d/2wMYZEBUfUooSyM3QO+6en8d8m1Vnao1f0cBdm21ASSTlz1eiomVHxOP7rurIBakDczue04kak0pdxWN7GdGtxWNzEdGu/AUv35Ns=
UksHMXRJhCZhWBUE
